act通过对荚膜多糖乙酰化修饰增强ST11-KL64型碳青霉烯耐药肺炎克雷伯菌毒力的机制研究
批准号:
82102440
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
江建平
依托单位:
学科分类:
病原生物变异与耐药
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
江建平
中文摘要
碳青霉烯耐药肺炎克雷伯菌(CRKP)感染形势严峻,近年ST11-KL64型CRKP成为流行克隆且毒力增强,但毒力增强机制尚不明确,亟待阐明。申请人前期通过比较基因组学、基因敲除和小鼠试验发现乙酰转移酶基因act是ST11-KL64型CRKP重要毒力因子;乙酰化检测发现act可对荚膜多糖(CPS)乙酰化修饰,但修饰后分子结构不明;细菌刺激试验提示CPS乙酰化后可增强巨噬细胞促炎因子分泌;分子模拟提示CPS乙酰基与巨噬细胞TLR4共价结合。据此提出act通过对CPS乙酰化修饰增强ST11-KL64型CRKP毒力的假说。我们拟通过酶活测定、核磁共振等,揭示乙酰化修饰CPS分子结构及抗原性改变;通过CPS刺激巨噬细胞等试验,明确CPS乙酰化对巨噬细胞分泌促炎因子影响及TLR4在其中的作用;通过分子流行病学分析act在CRKP中流行特点。研究成果将有助于CRKP感染防治,为临床抗感染治疗提供新思路。
英文摘要
Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections are critical in clinical settings. Recent studies showed that the CRKP belonging to ST11-KL64 have become a major clone in China and their virulence has enhanced. However, the mechanisms behind the virulence enhancement are poorly understood and therefore need to be illuminated. In preliminary studies, we identified an acyltransferase encoding gene act, which plays important roles in virulence enhancement of ST11-KL64 CRKP, by comparative genomics, gene knockouts and mouse lethality studies. By acetylation analysis, we found that act could acetylate the capsular polysaccharide (CPS) of ST11-KL64 CRKP, however, the molecular structure of acetylated CPS remained to be investigated. Furthermore, experiments from co-culture of bacteria and macrophages indicated that acetylated CPS could enhance the secretion of proinflammatory factors in macrophages and the molecular modeling showed that the acetyl group in CPS can covalently bound to TLR4. Taken together, we hypothesized that act enhances the virulence of ST11-KL64 CRKP by acetylating the CPS. To validate our hypothesis, we will determine the molecular structure and antigenic changes of acetylated CPS by enzymatic experiments and NMR, the effects of acetylated CPS and TLR4 in the secretion of proinflammatory factors of macrophages by stimulation experiments, and epidemiology features of act in CRKP by epidemiology analyses. Our findings will facilitate and provide new insights in the treatment of CRKP infections in clinical practices.
碳青霉烯耐药肺炎克雷伯菌(CRKP)感染形势严峻,近年ST11-KL64型CRKP成为流行克隆且毒力增强,亟待阐明其机制。申请人前期发现act通过改变荚膜多糖(CPS)功能而增强ST11-KL64型CRKP毒力,但其分子机制不明。依托本项目,申请人通过大量实验证实act是ST11-KL64毒力增强重要因子,act敲除株CPS含量减少,抗原性降低,其生物膜形成能力增强。细胞试验表明act敲除株对中性粒细胞吞噬杀伤的抵抗能力减弱,其介导巨噬细胞促炎因子分泌减少。小鼠试验证明,act敲除株在小鼠各脏器载量显著降低,小鼠组织病理学炎症反应明显减轻。申请人进一步对ST11-KL64型CRKP尿路感染患者进行跟踪随访,发现菌株在感染过程中发生act缺失后,患者感染症状消退,带菌生存,菌株毒力明显减弱,从而在现实世界中进一步证实本项目研究发现。以上研究内容,申请人作为通讯作者并标准本课题号的论文已发表。
国内基金
海外基金